- Home
- PTON vs HRMY Comparison
PTON vs HRMY Comparison
Compare PTON & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTON | HRMY |
|---|---|---|
| Founded | 2012 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.2B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PTON | HRMY |
|---|---|---|
| Price | $5.36 | $38.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 9 |
| Target Price | $7.89 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 8.9M | 723.0K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.67 | 7.97 |
| EPS | 0.14 | ★ 1.84 |
| Revenue | N/A | ★ $868,453,000.00 |
| Revenue This Year | N/A | $19.75 |
| Revenue Next Year | $0.44 | $12.88 |
| P/E Ratio | $38.64 | ★ $20.73 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $3.65 | $25.52 |
| 52 Week High | $9.20 | $40.87 |
Technical Indicators
Market Signals| Indicator | PTON | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 40.96 | 55.24 |
| Support Level | $4.98 | $34.87 |
| Resistance Level | $6.00 | $39.40 |
| Average True Range (ATR) | 0.23 | 1.21 |
| MACD | -0.05 | -0.11 |
| Stochastic Oscillator | 10.92 | 40.91 |
Price Performance
Historical ComparisonAbout PTON Peloton Interactive Inc.
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Products derive revenue from the portfolio of Connected Fitness Products and related accessories, as well as Precor-branded fitness products, delivery and installation services, Peloton Bike portfolio rental products, extended warranty agreements, branded apparel, and commercial service contracts. Subscription revenue is derived from monthly Subscription fees. The company generates maximum revenue from the Subscription segment. Geographically, the company derives a majority of its revenue from North America and the rest from International markets.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.